Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872–85. https://doi.org/10.1056/NEJMra0902908.

Article  CAS  PubMed  Google Scholar 

Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45–52. https://doi.org/10.1182/blood-2008-01-134858.

Article  CAS  PubMed  Google Scholar 

Aoudjhane M, Labopin M, Gorin N-C, Shimoni A, Ruutu T, Kolb H-J, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19:2304–12.

Article  CAS  PubMed  Google Scholar 

Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, et al. Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial. Transplant Cell Ther. 2021;27:483.e1–483.e6.

Article  PubMed  Google Scholar 

Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006;20:322–8.

Article  CAS  PubMed  Google Scholar 

Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–46.

Article  CAS  PubMed  Google Scholar 

Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006;12:1047–55.

Article  PubMed  Google Scholar 

Flynn CM, Hirsch B, DeFor T, Barker JN, Miller JS, Wagner JE, et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol. 2007;82:867–72.

Article  PubMed  Google Scholar 

Ringdén O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol. 2009;27:4570–7.

Article  PubMed  Google Scholar 

Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb H-J. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5675–87.

Article  PubMed  Google Scholar 

Holtick U, Shimabukuro-Vornhagen A, Chakupurakal G, Theurich S, Leitzke S, Burst A, et al. FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission. Eur J Haematol. 2016;96:475–82.

Article  PubMed  Google Scholar 

Rodriguez-Arboli E, Labopin M, Tischer J, Brecht A, Ganser A, Finke J, et al. FLAMSA-based reduced-intensity conditioning versus myeloablative conditioning in younger patients with relapsed/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2020;26:2165–73. https://doi.org/10.1016/j.bbmt.2020.07.020.

Article  CAS  PubMed  Google Scholar 

Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant. 2012;18:1211–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Konuma T, Shimomura Y, Ozawa Y, Ueda Y, Uchida N, Onizuka M, et al. Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: a propensity score matched analysis. Hematol Oncol. 2019;37:85–95.

Article  CAS  PubMed  Google Scholar 

Scheid C, Eikema D-J, Van Gelder M, Salmenniemi U, Maertens J, Passweg J, et al. Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms? Blood. 2024;144:445–56.

Article  CAS  PubMed  Google Scholar 

Schmid C, Schleuning M, Tischer J, Holler E, Haude K-H, Braess J, et al. Early allogeneic hematopoietic cell transplantation for AML with a complex aberrant karyotype-results from a prospective pilot study. Bone Marrow Transplant. 2012;47:46–53.

Chemnitz JM, von Lilienfeld-Toal M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Krause A, et al. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. Ann Hematol. 2012;91:47–55.

Article  CAS  PubMed  Google Scholar 

Holtick U, Herling M, Pflug N, Chakupurakal G, Leitzke S, Wolf D, et al. Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML. Ann Hematol. 2017;96:479–87.

Article  CAS  PubMed  Google Scholar 

Saraceni F, Labopin M, Brecht A, Kröger N, Eder M, Tischer J, et al. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). J Hematol Oncol. 2019;12:1–10.

Article  Google Scholar 

Sheth V, Labopin M, Canaani J, Volin L, Brecht A, Ganser A, et al. Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. Bone Marrow Transplant. 2019;54:531–9. https://doi.org/10.1038/s41409-018-0288-0.

Article  CAS  PubMed  Google Scholar 

Braitsch K, Schwarz A, Koch K, Hubbuch M, Menzel H, Keller U, et al. Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis. Ann Hematol. 2022;101:1311–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kröger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, et al. Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study). J Clin Oncol. 2021;39:3318–27.

Article  PubMed  Google Scholar 

Hellström-Lindberg ES, Kröger N. Clinical decision-making and treatment of myelodysplastic syndromes. Blood. 2023;142:2268–81.

Article  PubMed  Google Scholar 

Niederwieser C, Kroeger N. Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome. Best Pract Res Clin Haematol. 2021;34:101332.

Article  CAS  PubMed  Google Scholar 

Kröger N. Induction, bridging, or straight ahead: the ongoing dilemma of allografting in advanced myelodysplastic syndrome. Biol Blood Marrow Transplant. 2019;25:e247–e9.

Article  PubMed  Google Scholar 

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.

Article  PubMed  PubMed Central  Google Scholar 

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.

CAS  PubMed  Google Scholar 

Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.

Article  PubMed  Google Scholar 

Yahng S-A, Kim M, Kim T-M, Jeon Y-W, Yoon J-H, Shin S-H, et al. Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts. Oncotarget. 2016;8:12342.

Article  PubMed Central  Google Scholar 

Massoud R, Klyuchnikov E, Steiner N, Zeck G, Heidenreich S, Langebrake C et al. Sequential conditioning with FLAMSA does not improve outcomes of allogeneic stem cell transplantation in chronic myelomonocytic leukemia patients. Transpl Cell Ther. 2024. https://doi.org/10.1016/j.jtct.2024.10.003

Potter V, Gras L, Koster L, Kroger N, Sockel K, Ganser A, et al. Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2024;59:224–31.

Article  CAS  PubMed